Antiangiogenic strategies in breast cancer management

Monica Giovannini, Daniela Aldrighetti, Patrizia Zucchinelli, Carmen Belli, Eugenio Villa

Research output: Contribution to journalArticlepeer-review


Angiogenesis is considered one of the key mechanisms of tumour growth and survival. Therefore it represents an ideal pharmaceutical target. Many antiangiogenic agents have been developed so far in several solid tumours and also in breast cancer. Vascular endothelial growth factor (VEFG) is the main target and both monoclonal antibodies and small molecules belonging to the tyrosine kinase inhibitors directed against VEGF(R) have been developed. Some other therapeutic approaches have shown to exert some antiangiogenic activity, such as hormonal agents, metronomic chemotherapy, bisphosphonates and others. In this paper we provide an introduction of the current data supporting the angiogenesis in breast cancer and a review of the most relevant antiagiogenic therapies which have been investigated so far.

Original languageEnglish
Pages (from-to)13-35
Number of pages23
JournalCritical Reviews in Oncology/Hematology
Issue number1
Publication statusPublished - Oct 2010


  • Antiangiogenic agents
  • Bisphosphonates
  • Breast cancer angiogenesis
  • COX-2 inhibitors
  • Hormonal therapy
  • Metronomic chemotherapy
  • Monoclonal antibodies
  • Tyrosin kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology


Dive into the research topics of 'Antiangiogenic strategies in breast cancer management'. Together they form a unique fingerprint.

Cite this